NO20016114D0 - Preparater og fremgangsmåter for å öke kolesterol utströmming og heve HDL ved ATP-bindingskassett-transportörprotein ABC 1 - Google Patents

Preparater og fremgangsmåter for å öke kolesterol utströmming og heve HDL ved ATP-bindingskassett-transportörprotein ABC 1

Info

Publication number
NO20016114D0
NO20016114D0 NO20016114A NO20016114A NO20016114D0 NO 20016114 D0 NO20016114 D0 NO 20016114D0 NO 20016114 A NO20016114 A NO 20016114A NO 20016114 A NO20016114 A NO 20016114A NO 20016114 D0 NO20016114 D0 NO 20016114D0
Authority
NO
Norway
Prior art keywords
preparations
methods
carrier protein
atp binding
cartridge carrier
Prior art date
Application number
NO20016114A
Other languages
English (en)
Other versions
NO20016114L (no
Inventor
Richard Mark Lawn
David Wade
Michael Garvin
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20016114D0 publication Critical patent/NO20016114D0/no
Publication of NO20016114L publication Critical patent/NO20016114L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Addiction (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
NO20016114A 1999-06-18 2001-12-14 Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 NO20016114L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14026499P 1999-06-18 1999-06-18
US15387299P 1999-09-14 1999-09-14
US16657399P 1999-11-19 1999-11-19
PCT/US2000/016765 WO2000078972A2 (en) 1999-06-18 2000-06-16 Regulation with binding cassette transporter protein abc1

Publications (2)

Publication Number Publication Date
NO20016114D0 true NO20016114D0 (no) 2001-12-14
NO20016114L NO20016114L (no) 2002-02-12

Family

ID=27385472

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20016114A NO20016114L (no) 1999-06-18 2001-12-14 Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1
NO20016121A NO20016121L (no) 1999-06-18 2001-12-14 Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20016121A NO20016121L (no) 1999-06-18 2001-12-14 Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1

Country Status (19)

Country Link
EP (2) EP1190065A2 (no)
JP (4) JP2003508031A (no)
KR (2) KR100476519B1 (no)
CN (2) CN100513570C (no)
AR (2) AR024391A1 (no)
AT (1) ATE422545T1 (no)
AU (3) AU777461B2 (no)
BR (2) BR0011696A (no)
CA (2) CA2375781A1 (no)
DE (1) DE60041545D1 (no)
HK (2) HK1046427A1 (no)
IL (2) IL147022A0 (no)
MX (2) MXPA01013175A (no)
NO (2) NO20016114L (no)
NZ (3) NZ516061A (no)
SG (2) SG121852A1 (no)
TR (2) TR200200440T2 (no)
TW (2) TWI304737B (no)
WO (2) WO2000078971A2 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854880A1 (en) * 1999-03-15 2007-11-14 University of British Columbia Methods and reagents for modulating cholesterol levels
JP4726302B2 (ja) 1999-03-15 2011-07-20 ユニバーシティ オブ ブリティッシュ コロンビア Ａｂｃ１ポリペプチドおよびコレステロール水準を調節する方法と試薬
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
AU1291901A (en) * 1999-09-01 2001-03-26 University Of British Columbia, The Compositions and methods for modulating hdl cholesterol and triglyceride levels
US6555323B2 (en) * 2000-02-08 2003-04-29 Pfizer Inc. Assay for ABCA1
US7378274B2 (en) 2000-05-02 2008-05-27 Aventis Pharma S.A. Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses
EP1203588A1 (en) * 2000-11-06 2002-05-08 Bayer Ag Sterol-independent regulation of ABC1 promoter via oncostatinM
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
AU2002317093A1 (en) * 2001-07-03 2003-01-21 University Of British Columbia Screening processes for agents modulating cholesterol levels
JPWO2003033023A1 (ja) * 2001-10-12 2005-02-03 グレラン製薬株式会社 低ｈｄｌ血症改善剤
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
WO2003060078A2 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ATE496893T1 (de) 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc Isochinolinonderivate und deren verwendung als medikamente
BRPI0412262A (pt) 2003-07-23 2006-09-19 X Ceptor Therapeutics Inc derivados de azepina como agentes farmacêuticos
WO2005116057A1 (en) * 2004-05-27 2005-12-08 Baker Medical Research Institute Monoclonal antibody against abca1
WO2006122787A1 (en) 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
KR101414438B1 (ko) 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
AU2006261841B8 (en) 2005-06-27 2012-12-06 Exelixis Patent Company Llc Pyrazole based LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US8119686B2 (en) 2006-11-24 2012-02-21 Hykes Laboratories Llc Spiroquinone compound and pharmaceutical composition
EP2557090A3 (en) 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
BRPI0819656A2 (pt) 2007-11-27 2015-06-23 Ablynx Nv Seqüências de aminoácidos contras citocinas heterodiméricas e/ou seus receptores e polipeptídeos compreendendo as mesmas
EP2247616A2 (en) 2008-03-05 2010-11-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
EP2260058A2 (en) 2008-04-07 2010-12-15 Ablynx N.V. Single variable domains against the notch pathways
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
WO2010120508A2 (en) * 2009-03-31 2010-10-21 The General Hospital Corporation Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders
CN102388069B (zh) 2009-04-10 2016-01-20 埃博灵克斯股份有限公司 用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽
CA2761934C (en) 2009-05-28 2018-01-09 Exelixis Patent Company Llc Substituted 1-(biphenyl-4-yl)-2-benzyl-4-hydroxyalkyl-1h-imidazole compounds and their use as lxr modulators
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
WO2012062713A1 (en) 2010-11-08 2012-05-18 Novartis Ag Cxcr2 binding polypeptides
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
CN104271598A (zh) 2011-06-23 2015-01-07 埃博灵克斯股份有限公司 针对IgE的免疫球蛋白单可变结构域
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2013188740A1 (en) 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
US9101745B2 (en) * 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
CN105188380B (zh) 2013-03-15 2017-08-15 百时美施贵宝公司 Lxr调节剂
EP2968275B1 (en) 2013-03-15 2017-11-29 Bristol-Myers Squibb Company Lxr modulators
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
GB201315136D0 (en) * 2013-08-23 2013-10-09 Univ Glasgow Cholesterol modulation
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
SG11201803976VA (en) 2015-11-27 2018-06-28 Ablynx Nv Polypeptides inhibiting cd40l
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
WO2018091606A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
KR20200013247A (ko) 2017-06-02 2020-02-06 아블린쓰 엔.브이. 아그레칸 결합 면역글로불린
EP3630847A1 (en) 2017-06-02 2020-04-08 Merck Patent GmbH Adamts binding immunoglobulins
JP7249961B2 (ja) 2017-06-02 2023-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
BR112019025097A2 (pt) 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação a mmp13
CN115433733A (zh) 2021-06-04 2022-12-06 生物岛实验室 环状RNA Circ-ACE2翻译的多肽及其应用
CN114369162B (zh) 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378274B2 (en) * 2000-05-02 2008-05-27 Aventis Pharma S.A. Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses

Also Published As

Publication number Publication date
JP2005112859A (ja) 2005-04-28
EP1218515B1 (en) 2009-02-11
CA2375787A1 (en) 2000-12-28
TWI304737B (en) 2009-01-01
SG121853A1 (en) 2006-05-26
DE60041545D1 (de) 2009-03-26
JP2003506097A (ja) 2003-02-18
CN100513570C (zh) 2009-07-15
CN1379817A (zh) 2002-11-13
HK1046427A1 (zh) 2003-01-10
AU5746700A (en) 2001-01-09
HK1046708A1 (zh) 2003-01-24
WO2000078972A9 (en) 2002-07-18
IL147021A0 (en) 2002-08-14
JP2006137750A (ja) 2006-06-01
KR20020012612A (ko) 2002-02-16
SG121852A1 (en) 2006-05-26
AU5743400A (en) 2001-01-09
NO20016114L (no) 2002-02-12
JP2003508031A (ja) 2003-03-04
NZ516061A (en) 2004-04-30
IL147022A0 (en) 2002-08-14
WO2000078972A3 (en) 2002-05-02
TR200200440T2 (tr) 2002-09-23
AR024391A1 (es) 2002-10-02
AU777461B2 (en) 2004-10-14
ATE422545T1 (de) 2009-02-15
CA2375787C (en) 2007-03-27
CA2375781A1 (en) 2000-12-28
KR20020012281A (ko) 2002-02-15
BR0011696A (pt) 2002-04-30
KR100476519B1 (ko) 2005-03-17
WO2000078971A3 (en) 2002-01-17
MXPA01013175A (es) 2002-06-04
NO20016121D0 (no) 2001-12-14
WO2000078972A2 (en) 2000-12-28
CN1434865A (zh) 2003-08-06
AU2005200171A1 (en) 2005-02-10
MXPA01013174A (es) 2002-06-04
TWI259205B (en) 2006-08-01
WO2000078972A8 (en) 2001-06-21
EP1190065A2 (en) 2002-03-27
EP1218515A2 (en) 2002-07-03
TR200200441T2 (tr) 2002-11-21
NO20016121L (no) 2002-02-12
AR024576A1 (es) 2002-10-16
JP4277956B2 (ja) 2009-06-10
BR0011753A (pt) 2002-04-30
NZ531401A (en) 2005-08-26
WO2000078971A2 (en) 2000-12-28
NZ529785A (en) 2005-09-30
TW200626176A (en) 2006-08-01

Similar Documents

Publication Publication Date Title
NO20016121D0 (no) Preparater og fremgangsmåter for å öke kolesterol utströmming og heve HDL ved ATP-bindingskassett-transportörprotein ABC 1
NO995164D0 (no) Preparat for å kontrollere skadelige bioorganismer og fremgangsmåte for å kontrollere skadelige bioorganismer ved anvendelse derav
IS5058A (is) Samverkandi súlfónýlþvagefnis-glitasónsblöndur við sykursýki
NO995660D0 (no) Fremgangsmåte ved kommunikasjon og anordning for samme
AU4678600A (en) Aza-benzazolium containing cyanine dyes
NO20030167L (no) Fremgangsmåte og system for å forenkle transaksjoner ved trådlös e-handel
DE69706064T2 (de) Intermodulationsausgleich in mehrkanal-verstärkern
IS6040A (is) Valdekoxib efnablöndur
NO20001554D0 (no) Fremgangsmåter og mellomprodukter nyttige for å fremstille antifolater
NO20020779D0 (no) Fremgangsmåter, preparater og sett for å fremme helbredelse ved skader på sentralnervesystemet
FR2759641B1 (fr) Capote hard top pour cabriolet
AU1221201A (en) Antisense modulation of y-box binding protein 1 expression
DE69804635D1 (de) Verzweigte alkoxy-substituierte 2-aminopyridine als nos inhibitoren
DK0867192T3 (da) Kombinationspræparat til anvendelse ved demens
NO20022057D0 (no) Fremgangsmåte og sammensetning for å behandle lungesykdommer
EP1059579A3 (en) Information processor and method for switching register files
NO993354D0 (no) Voksholdige preparater
GB0101090D0 (en) Synergistic compositions comprising ascorbate and lysine for states related to extra cellular matrix degeneration
IT1299743B1 (it) Cerniera per mobili
AU2002218744A1 (en) Bax fragment induced tumor cell death
HUP0203195A3 (en) Redox reversible hcv proteins with native-like conformation
TR199501049A2 (tr) Metalürjik dönüsümde veya bununla ilgili gelismeler.
AU8855798A (en) Novel composition for treating, preventing and/or delaying ischemic cell death
AU4277899A (en) Tnfr-like protein with death domain
DE29601578U1 (de) Dreiteilige Stahlumfassungszarge